Immunomodulatory functions of hyaluronate in the LEW-to-F344 model of chronic cardiac allograft rejection

Transplantation

Volumn 67, Issue 6, 1999, Pages 909-914

  Knoflach, Andreas ^a,b   Magee, Colm ^a,b   Denton, Mark D ^a,b   Kim, Kjung Soo ^a,b   Buelow, Roland ^c   Hancock, Wayne W ^a,b   Sayegh, Mohamed H ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c GENZYME CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; HERMES ANTIGEN; HYALURONIC ACID;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0033608809     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199903270-00020     Document Type: Article

References (29)

1. Paul LC. Chronic renal transplant loss. Kidney Int 1995; 47(6): 1491.
2. Adams DH, Russell ME, Hancock WW, Sayegh MH, Wyner LR, Karnovsky MJ. Chronic rejection in experimental cardiac transplantation: studies in the Lewis-F344 model. Immunol Rev 1993; 134(5): 5.
3. Tullius SG, Tilney NL. Both alloantigen-dependent and -independent factors influence chronic allograft rejection. Transplantation 1995; 59(3): 313.
4. Fuggle SV, Koo DD. Cell adhesion molecules in clinical renal transplantation. Transplantation 1998; 65(6): 763.
5. DeGrendele HC, Estess P, Picker LJ, Siegelman MH. CD44 and its ligand hyaluronate mediate rolling under physiologic flow: a novel lymphocyte-endothelial cell primary adhesion pathway. J Exp Med 1996; 183(3): 1119.
6. DeGrendele HC, Estess P, Siegelman MH. Requirement for CD44 in activated T cell extravasation into an inflammatory site. Science 1997; 278(5338): 672.
7. Lesley J, Hyman R, Kincade PW. CD44 and its interaction with extracellular matrix. Adv Immunol 1993; 54: 271.
8. DeGrendele HC, Kosfiszer M, Estess P, Siegelman MH. CD44 activation and associated primary adhesion is inducible via T cell receptor stimulation. J Immunol 1997; 159(6): 2549.
9. Oksala O, Salo T, Tammi R, et al. Expression of proteoglycans and hyaluronan during wound healing. J Histochem Cytochem 1995; 43(2): 125.
10. Bartolazzi A, Peach R, Aruffo A, Stamenkovic I. Interaction between CD44 and hyaluronate is directly implicated in the regulation of tumor development. J Exp Med 1994; 180(1): 53.
11. Tammi R, Paukkonen K, Wang C, Horsmanheimo M, Tammi M. Hyaluronan and CD44 in psoriatic skin: intense staining for hyaluronan on dermal capillary loops and reduced expression of CD44 and hyaluronan in keratinocyte-leukocyte interfaces. Arch Dermatol Res 1994; 286(1): 21.
12. Noble PW, McKee CM, Cowman M, Shin HS. Hyaluronan fragments activate an NF-kappa B/I-kappa B alpha autoregulatory loop in murine macrophages. J Exp Med 1996; 183(5): 2373.
13. Guo YJ, Ma J, Wong JH, et al. Monoclonal anti-CD44 antibody acts in synergy with anti-CD2 but inhibits anti-CD3 or T cell receptor-mediated signaling in murine T cell hybridomas. Cell Immunol 1993; 152(1): 186.
14. Guo Y, Wu Y, Shinde S, Sy MS, Aruffo A, Liu Y. Identification of a costimulatory molecule rapidly induced by CD40L as CD44H. J Exp Med 1996; 184(3): 955.
15. Turley EA. Hyaluronan and cell locomotion. Cancer Metastasis Rev 1992; 11(1): 21.
16. Zhang S, Chang MC, Zylka D, Turley S, Harrison R, Turley EA. The hyaluronan receptor RHAMM regulates extracellular-regulated kinase. J Biol Chem 1998; 273(18): 11342.
17. McCourt PA, Ek B, Forsberg N, Gustafson S. Intercellular adhesion molecule-1 is a cell surface receptor for hyaluronan. J Biol Chem 1994; 269(48): 30081.
18. Hofmann M, Fieber C, Assmann V, et al. Identification of IHABP, a 95 kDa intracellular hyaluronate binding protein. J Cell Sci 1998; 111(Pt 12): 1673.
19. Nemec RE, Toole BP, Knudson W. The cell surface hyaluronate binding sites of invasive human bladder carcinoma cells. Biochem Biophys Res Commun 1987; 149(1): 249.
20. Zeng C, Toole BP, Kinney SD, Kuo JW, Stamenkovic I. Inhibition of tumor growth in vivo by hyaluronan oligomers. Int J Cancer 1998; 77(3): 396.
21. Knoflach A, Azuma H, Magee C, et al. Immunomodulatory functions of low molecular weight hyaluronate in an acute rat renal allograft rejection model. J Am Soc Nephrol (in press).
22. Russell ME, Hancock WW, Akalin E, et al. Chronic cardiac rejection in the LEW to F344 rat model: blockade of CD28-B7 costimulation by CTLA4Ig modulates T cell and macrophage activation and attenuates arteriosclerosis. J Clin Invest 1996; 97(3): 833.
23. Hancock WH, Whitley WD, Tullius SG, et al. Cytokines, adhesion molecules, and the pathogenesis of chronic rejection of rat renal allografts. Transplantation 1993; 56(3): 643.
24. Carpenter CB. Long-term failure of renal transplants: adding insult to injury. Kidney Int Suppl 1995; 50: S40.
25. Estess P, DeGrendele HC, Pascual V, Siegelman MH. Functional activation of lymphocyte CD44 in peripheral blood is a marker of autoimmune disease activity [see comments]. J Clin Invest 1998; 102(6): 1173.
26. Mohamadzadeh M, DeGrendele H, Arizpe H, Estess P, Siegelman M. Proinflammatory stimuli regulate endothelial hyaluronan expression and CD44/HA-dependent primary adhesion. J Clin Invest 1998; 101(1): 97.
27. Seiter S, Weber B, Tilgen W, Zoller M. Down-modulation of host reactivity by anti-CD44 in skin transplantation. Transplantation 1998; 66(6): 778.
28. Laman JD, Maassen CB, Schellekens MM, et al. Therapy with antibodies against CD40L (CD154) and CD44-variant isoforms reduces experimental autoimmune encephalomyelitis induced by a proteolipid protein peptide. Mult Scler 1998; 4(3): 147.
29. Routledge MW, Rush D, McKenna R, et al. The receptor for hyaluronan-mediated motility is expressed in human renal allografts and is correlated with Banff chronic rejection scores. Transplant Proc 1997; 29(6): 2603.